Mainz Biomed N.V (MYNZ) Net Income towards Common Stockholders: 2022-2023
Historic Net Income towards Common Stockholders for Mainz Biomed N.V (MYNZ) over the last 2 years, with Dec 2023 value amounting to -$5.2 million.
- Mainz Biomed N.V's Net Income towards Common Stockholders rose 36.70% to -$5.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$26.3 million, marking a year-over-year increase of 0.35%. This contributed to the annual value of -$21.7 million for FY2024, which is 17.82% up from last year.
- Per Mainz Biomed N.V's latest filing, its Net Income towards Common Stockholders stood at -$5.2 million for Q4 2023, which was up 17.72% from -$6.3 million recorded in Q3 2023.
- Over the past 5 years, Mainz Biomed N.V's Net Income towards Common Stockholders peaked at -$5.2 million during Q4 2023, and registered a low of -$8.3 million during Q2 2023.
- In the last 2 years, Mainz Biomed N.V's Net Income towards Common Stockholders had a median value of -$6.4 million in 2023 and averaged -$6.6 million.
- The largest annual percentage gain for Mainz Biomed N.V's Net Income towards Common Stockholders in the last 5 years was 36.70% (2023), contrasted with its biggest fall of 18.92% (2023).
- Quarterly analysis of 2 years shows Mainz Biomed N.V's Net Income towards Common Stockholders stood at -$8.2 million in 2022, then surged by 36.70% to -$5.2 million in 2023.
- Its last three reported values are -$5.2 million in Q4 2023, -$6.3 million for Q3 2023, and -$8.3 million during Q2 2023.